Your browser doesn't support javascript.
loading
Development of a single-chain variable antibody fragment against a conserved region of the SARS-CoV-2 spike protein.
Gao, Tingyu; Irie, Atsushi; Kouwaki, Takahisa; Oshiumi, Hiroyuki.
Afiliação
  • Gao T; Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Irie A; Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. airie@gpo.kumamoto-u.ac.jp.
  • Kouwaki T; Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Oshiumi H; Department of Immunology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. oshiumi@kumamoto-u.ac.jp.
Sci Rep ; 14(1): 14419, 2024 06 22.
Article em En | MEDLINE | ID: mdl-38909102
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prolonged the duration of the pandemic because of the continuous emergence of new variant strains. The emergence of these mutant strains makes it difficult to detect the virus with the existing antibodies; thus, the development of novel antibodies that can target both the variants as well as the original strain is necessary. In this study, we generated a high-affinity monoclonal antibody (5G2) against the highly conserved region of the SARS-CoV-2 spike protein to detect the protein variants. Moreover, we generated its single-chain variable antibody fragment (sc5G2). The sc5G2 expressed in mammalian and bacterial cells detected the spike protein of the original SARS-CoV-2 and variant strains. The resulting sc5G2 will be a useful tool to detect the original SARS-CoV-2 and variant strains.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos de Cadeia Única / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos de Cadeia Única / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / Anticorpos Antivirais Limite: Animals / Humans Idioma: En Revista: Sci Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão